Asia-Pacific is reshaping the global Orphan Drugs Market with a projected CAGR of 12.18% through 2035. China expanded its National Rare Disease List to 207 conditions and introduced zero-tariff import policies for designated orphan drugs. Japan's SAKIGAKE accelerated pathway and South Korea's conditional approval framework are compressing timelines for small-population therapies. India's updated National Policy for Rare Diseases provides government-crowdfunding support up to INR 50 Lakh per patient. These policy shifts, combined with diagnostic infrastructure investments and newborn screening expansion, are unlocking a USD 40+ billion addressable opportunity by 2032.

Q1. What is Asia-Pacific's projected CAGR in the Orphan Drugs Market? A. The region is forecast to grow at 12.18% CAGR from 2026 to 2035.

Q2. How many conditions are on China's National Rare Disease List? A. China has listed 207 rare disease conditions as of 2023.

Q3. Which Asian country offers an accelerated approval pathway? A. Japan's SAKIGAKE designation provides accelerated review for rare disease therapies.